Search Results (648)

Metabolic-associated steatotic liver disease (MASLD) affects an estimated 25–30% of the global adult population and represents a leading cause of liver-related morbidity. However, approved pharmacological therapies remain strictly limited. AMP-activated protein kinase (AMPK), a highly conserved heterotrimeric serine/threonine kinase and major regulator of cellular energy homeostasis, is chronically suppressed in the steatotic liver through hyperinsulinemia, ceramide signaling, oxidative stress, and epigenetic silencing of its upstream activator LKB1. This suppression removes a critical brake on de novo lipogenesis while simultaneously impairing fatty acid β-oxidation, mitochondrial quality control, anti-inflammatory signaling, and hepatic stellate cell quiescence. Thus, AMPK restoration may serve as an effective strategy capable of addressing multiple pathological drivers of MASLD. This review examines the molecular architecture of the AMPK heterotrimer, the downstream signaling networks governing hepatic lipid metabolism, glucose homeostasis, and fibrogenesis, and a spectrum of AMPK-activating pharmacology relevant to MASLD. Furthermore, it would introduce indirect activators including metformin, berberine, resveratrol, and related phytochemicals, as well as direct allosteric activators targeting the ADaM site, such as A-769662, PF-06409577, MK-8722, Compound 991, and the clinical-stage compound O304. Translational challenges confronting this therapeutic class are critically evaluated. Full article

Objectives: This study aimed to explore the combined regulatory effects of probiotics combined with bioactive compounds on intestinal immunity and mucosal barrier function. Methods: Fifty specific-pathogen-free (SPF) male Kunming mice (5–6 weeks old, weighing 20 ± 2 g) were randomly assigned to five groups (n = 10 per group): blank control (C), lipopolysaccharide-induced model (LPS), probiotic (PB), antioxidant (AO), and combined treatment (PB/AO). The C and LPS groups received daily oral gavage of 0.5 mL sterile 0.9% saline. The PB group received a daily gavage of 1 × 10⁸ CFU/mL Pediococcus acidilactici lindner and Lactobacillus plantarum. The AO group was administered a daily gavage of berberine (30 mg/kg BW), wogonin (30 mg/kg BW), and sodium butyrate (200 mg/kg BW). The PB/AO group received a daily gavage combining the probiotic mixture (1 × 10⁸ CFU/mL) with the plant extracts (30 mg/kg BW berberine, 30 mg/kg BW wogonin, and 200 mg/kg BW sodium butyrate). Following a 14-day preventive intervention, all groups except C were intraperitoneally injected with LPS to induce inflammation. Indices of visceral organs, serum antioxidant and immune parameters, ileal histomorphology, gut microbiota composition, and the expression of key barrier- and inflammation-related genes were comprehensively evaluated. Results: LPS exposure increased liver and spleen coefficients. PB/AO treatment significantly reduced the LPS-induced elevation of liver coefficient to a level comparable to that of the C group; however, no significant improvement in spleen coefficient was observed. In terms of antioxidant and immune indices, all intervention groups increased the levels of SOD, GSH-Px, and T-AOC to varying degrees, and decreased the levels of MDA and inflammatory factors (TNF-α, IL-1β, IL-6, and DAO), with the PB/AO group showing the most significant improvement (p < 0.01). Ileal microbiome analysis showed that PB/AO treatment enriched Firmicutes, Lactococcus and Lactobacillus but decreased Proteobacteria, with Clostridia as signature taxa. Mechanistically, PB/AO suppressed the transcription of NF-κB pathway-related genes (TLR4, MyD88 and NF-κB) and upregulated the expression of tight junction proteins (ZO-1, Claudin-1 and Occludin), thereby strengthening the intestinal barrier. Conclusions: In conclusion, co-administration of microbial probiotics and antioxidants achieves optimal protection against LPS-induced intestinal inflammation by jointly driving anti-inflammatory and antioxidative responses, modulating gut microbiota, and reinforcing barrier integrity. Full article

Obesity is recognized as a pathological condition that induces chronic low-grade systemic inflammation capable of affecting multiple organs, including the central nervous system, thereby promoting neuroinflammation. Although adipose and neural tissues differ in their structural and functional characteristics, they share common inflammatory mechanisms involving the TLR4/NF-κB/MAPK signaling pathways, the ROS/NRF2 axis, and the NLRP3 inflammasome. This review summarizes current evidence demonstrating the ability of berberine (BBR) to modulate these shared molecular pathways across different experimental models and pathophysiological conditions, with particular emphasis on obesity-induced neuroinflammation. A narrative literature search was conducted using academic search and indexing resources, including PubMed, Scopus, Web of Science, and Google Scholar, with the literature updated through 24 August 2026. The available evidence indicates that BBR modulates these signaling pathways, reduces the production of pro-inflammatory cytokines, attenuates oxidative stress, and limits glial activation. Furthermore, several studies suggest that BBR may help preserve the functional integrity of the blood–brain barrier and reduce neuronal damage associated with neuroinflammatory processes. Available evidence suggests that BBR may modulate inflammatory and oxidative pathways involved in obesity-associated neuroinflammation; however, current findings derive mainly from preclinical studies and indirect models. Future studies are needed to determine the bioavailability, central nervous system penetration, and clinical relevance of BBR. Full article

Highly aggressive gliomas remain difficult to treat because of their marked invasiveness, frequent recurrence, and association with glioma-related epilepsy. Increasing evidence suggests that ion channels expressed in glioma cells, including voltage-gated Na⁺ channels, large-conductance Ca²⁺-activated K⁺ (BK_Ca) channels, intermediate-conductance Ca²⁺-activated K⁺ (IK_Ca) channels, and inwardly rectifying K⁺ (Kir) channels, contribute to these malignant phenotypes and represent potential therapeutic targets. This perspective summarizes current evidence for eight representative drugs and phytoconstituents—perampanel, valproic acid, cilostazol, berberine, oxaliplatin, temozolomide, arecoline, and triptolide—that modulate these ion channels. Perampanel and valproic acid suppress voltage-gated Na⁺ current in glioma cells and may provide additional benefits in controlling glioma-associated epilepsy. Cilostazol activates BK_Ca channels, whereas berberine, oxaliplatin, and temozolomide inhibit IK_Ca channel activity. Arecoline suppresses IK_Ca and Kir channel activity, while triptolide inhibits Kir channels. These observations suggest that ion channel modulation may influence glioma cell proliferation, migration, invasion, and excitability. To complement the available experimental evidence, we performed molecular docking analyses as a hypothesis-generating approach to explore potential ligand–channel interactions. Because these computational predictions have not been experimentally validated, they should be interpreted cautiously and viewed as a framework for future mechanistic studies rather than definitive evidence of binding. We also discuss important translational considerations, including the limited clinical evidence and the toxicity profiles of several compounds. In particular, arecoline is associated with carcinogenicity and neurotoxicity, triptolide with significant systemic toxicity, berberine with poor oral bioavailability and potential drug interactions, and oxaliplatin with dose-limiting neurotoxicity. Overall, this perspective highlights ion channels as promising therapeutic targets in glioma while emphasizing the need for rigorous experimental validation and careful evaluation of safety before clinical translation. Full article

Obesity, diabetes, and dyslipidemia form an interconnected metabolic disease cluster driven by insulin resistance and chronic inflammation. This study evaluated the clinical efficacy and multi-target mechanisms of Coptidis Rhizoma for these metabolic disorders through an integrated systematic review, meta-analysis of randomized controlled trials (RCTs), network pharmacology, and molecular docking. Meta-analysis of 19 RCTs (n = 1718) demonstrated that Coptidis-containing formulations, primarily as adjunctive therapy, significantly improved primary clinical endpoints across all three metabolic conditions: body mass index (BMI: SMD = −0.72, 95% CI [−1.00, −0.44], p < 0.00001), glycated hemoglobin (HbA1c: SMD = −0.77, 95% CI [−1.07, −0.47], p < 0.00001), and low-density lipoprotein cholesterol (LDL-C: SMD = −1.10, 95% CI [−1.57, −0.62], p < 0.00001). Network analysis revealed shared targets enriched in lipid metabolism, inflammatory signaling, and PI3K-Akt/MAPK cascades. Molecular docking demonstrated favorable structural compatibility and predicted docking scores (ranging from −7.1 to −9.5 kcal/mol) of berberine toward key hub proteins, including PIK3CA, JAK2, MAOA, and PARP1. Consequently, Coptidis Rhizoma provides tangible clinical benefits across interconnected metabolic outcomes via the multi-target regulation of inflammatory and insulin signaling pathways. Clinically, Coptidis-containing formulations show promise as a complementary adjunct to conventional metabolic therapies, though future large-scale, standardized RCTs remain necessary to confirm long-term safety and optimize dosing regimens. Full article

Background/Objectives: The identification of acetylcholinesterase (AChE) inhibitors from complex natural matrices remains challenging due to the limitations of conventional colorimetric assays. This study aimed to develop a fluorescence-based AChE inhibition assay (FAIA) suitable for screening plant extracts, while simultaneously characterizing the metabolite profile of Berberis julianae fruits, identifying bioactive alkaloid-enriched fractions, and evaluating their cytotoxicity in neuronal cell models. Methods: Methanolic extracts of B. julianae fruits were profiled by HPLC-ESI-QTOF-MS/MS and fractionated using centrifugal partition chromatography (CPC). The developed FAIA, based on 4-methylumbelliferyl acetate as a fluorogenic substrate, was optimized and validated using berberine as a reference inhibitor. CPC fractions and selected protoberberine alkaloids were screened for AChE-inhibitory activity, while cytotoxicity was assessed in differentiated and undifferentiated SH-SY5Y cells using the resazurin assay. Results: Twenty-five metabolites, including eight isoquinoline alkaloids, were tentatively identified in the fruit extract. The optimized FAIA enabled reliable evaluation of AChE inhibition without the limitations associated with chromogenic assays. Among the CPC fractions, fraction 7 exhibited the strongest inhibitory activity. LC-MS analysis revealed that this fraction was enriched in protoberberine alkaloids, including berberine, palmatine, jatrorrhizine, magnocurarine, and demethyleneberberine. Cytotoxicity studies demonstrated concentration-dependent effects of both the isolated fractions and the individual alkaloids, with differentiated and undifferentiated SH-SY5Y cells exhibiting distinct sensitivity profiles. At 200 µg/mL, cell viability ranged from approximately 20–40% in undifferentiated SH-SY5Y cells and from approximately 25–45% in differentiated SH-SY5Y cells, depending on the CPC fraction. Among the tested protoberberine alkaloids, demethyleneberberine exhibited the lowest cytotoxic effect, maintaining the highest viability of differentiated SH-SY5Y cells, followed by jatrorrhizine and berberine. Conclusions: The proposed FAIA represents a sensitive and practical approach for screening AChE inhibitors in complex plant matrices. Combined with metabolomic profiling and CPC-based bioassay-guided fractionation, it enabled the identification of alkaloid-rich fractions of B. julianae with pronounced anti-AChE activity. These findings support the applicability of the developed workflow for natural-product-based drug discovery targeting neurodegenerative disorders. Full article

Background: Obesity is a multifaceted metabolic disorder characterized by systemic disturbances, particularly impaired energy homeostasis, chronic low-grade inflammation, and mitochondrial dysfunction across the brain, gut, adipose tissue, and liver axes. Objectives: This review aims to examine the metabolic properties and molecular mechanisms of six key phytochemicals (berberine, resveratrol, catechins, capsaicin, thymoquinone, and phycocyanin) and the exercise-induced myokine irisin, and their roles in mitochondrial signaling and metabolic reprogramming. Sources of Evidence: A comprehensive literature search was conducted across major electronic databases, including PubMed, Web of Science, and Scopus, to identify relevant mechanistic, in vivo, and in vitro studies. Results: Both the selected phytochemicals and irisin act as multi-target regulators that modulate key signaling pathways, including AMPK, PI3K/Akt/mTOR, SIRT1, Nrf2, and PPARγ. These phytochemicals and irisin can drive cell- and tissue-specific metabolic reprogramming, promoting the browning of white adipocytes, suppressing de novo lipogenesis in hepatocytes, and enhancing fatty acid oxidation in skeletal myocytes. This synergistic metabolic reprogramming enhances thermogenesis and increases energy expenditure. Conclusions: Co-targeting redox signaling and metabolic pathways via phytochemicals and irisin offers a powerful strategy against obesity. This integrative framework restores multi-organ homeostasis, laying the groundwork for targeted metabolic therapies. Full article

Endometriosis is a chronic, estrogen-dependent inflammatory condition that is marked by the growth of lesions outside the uterus, along with angiogenesis, fibrosis, immune dysregulation, and pain sensitization. There is now growing evidence that receptor tyrosine kinase (RTK) signaling networks are central to these processes, integrating proliferative, angiogenic, inflammatory, endocrine, and microenvironmental signals. This review summarizes the roles of six major RTK axes in endometriosis and evaluates their receptor-specific mechanisms, therapeutic relevance, and modulation by representative phytochemicals. An English-language literature search of PubMed was conducted with no publication date restrictions using combinations and variations of the following keywords: phytochemicals, endometriosis, EGFR, VEGFR, IGF1R, PDGFR, FGFR, MET, curcumin, resveratrol, epigallocatechin gallate (EGCG), quercetin, naringenin, berberine, apigenin, luteolin, genistein, and baicalein. Additional search terms related to receptor signaling mechanisms, downstream pathways, cellular phenotypes, and therapeutic relevance were also incorporated to ensure comprehensive coverage of the literature. The RTK signaling pathways control stromal activation, lesion survival, angiogenic support, extracellular matrix remodeling, neuroimmune sensitization, and malignant progression. Of the six RTK axes examined, EGFR, VEGFR, and IGF1R have the strongest mechanistic and pharmacological support, whereas PDGFR, FGFR, and MET remain biologically plausible targets. Even though phytochemicals do not consistently act as receptor-selective RTK inhibitors, evidence shows they reduce RTK-centred signaling networks by targeting common downstream hubs. As a result of their effects at the network level, the phytochemicals may help to suppress lesion proliferation, angiogenesis, invasion, fibrosis, inflammation, oxidative stress, and pain sensitization. Endometriosis should be viewed as an RTK-centered network disease rather than a single-pathway disorder. In this context, phytochemicals act as modulators that attenuate signaling hubs, offering a mechanistically aligned strategy for a disease driven by redundancy and microenvironmental crosstalk. Full article

Staphylococcus aureus (S. aureus), a primary exacerbating factor in eczema, remains a prevalent pathogenic public-health threat. The mechanism of mast cell/basophil degranulation in the context of S. aureus-exacerbated eczema remains unclear. We sought to investigate the direct effect of mast cell/basophil activation by S. aureus isolated from patients with severe eczema undergoing topical steroid withdrawal (TSW) and understand the mechanism of berberine (BBR) in inhibiting this activation. Clinical S. aureus strains (N = 8) were isolated from skin swabs of severe eczema patients and confirmed by sequencing. Human basophils (KU812), rat basophils (RBL-2H3) and murine mast cells (MC/9) were pre-treated with BBR for 48 h. and stimulated with heat-killed standard S. aureus- and clinical strains for 45 min, and degranulation was measured. BBR’s molecular-targets on basophils were identified by computational modeling and validated by qRT-PCR. BBR prevented degranulation following standard S. aureus stimulation in KU812, RBL-2H3 and MC/9 cells. BBR dose-dependently inhibited degranulation in KU812. BBR inhibited TNF-α and IL-4 release, and markedly suppressed the expression of FcεR1 (α, β, γ), TNFα, MAPK1, MAPK3, AKT2, CASP9, and CCND1 following standard S. aureus stimulation. BBR dose-dependently inhibited KU812 cell degranulation, markedly reduced TNF-α, IL-4, and MAPK1 and enhanced NFκB1A expression following clinical S. aureus strain stimulation. BBR inhibition of S. aureus-induced KU812 activation was at least associated with inhibition of MAPK-associated gene expression. This study provides novel insights into BBR’s effect in preventing S. aureus and human basophil interaction. Full article

Diabetic chronic wounds face multiple intractable healing obstacles including sustained inflammation, severe infection, insufficient angiogenesis and defective collagen deposition. Current dressings fail to simultaneously relieve all these pathological defects. Herein, we constructed a carrier-free binary self-assembled Glycyrrhizic acid monoammonium salt–Berberine (GB) hydrogel composed of berberine and glycyrrhizic acid monoammonium salt, which forms interconnected nanofiber networks via one-pot thermally assisted small-molecule co-assembly without chemical crosslinking or exogenous polymer carriers. Relying on intermolecular non-covalent interactions, this single supramolecular material integrates anti-inflammatory, broad-spectrum antibacterial, pro-angiogenic, and collagen-regenerative multifunctions, which simultaneously ameliorates multiple core pathological obstacles of diabetic wounds within one formulation. We systematically characterized its physicochemical features, biocompatibility, and antibacterial and anti-inflammatory activities, as well as in vivo wound repair performance. This hydrogel formed uniform nanofibrous architectures with favorable viscoelastic properties and pH-dependent sustained release. In vitro assays verified its outstanding biosafety, broad-spectrum bacteriostasis against Escherichia coli and Staphylococcus aureus, and potent inhibitory effects on pro-inflammatory cytokines TNF-α and IL-6, with bacterial inhibition rates reaching ~88% against E. coli and ~70% against S. aureus. In diabetic mouse full-thickness infected wound models, the GB hydrogel simultaneously alleviated local inflammation, accelerated wound closure and facilitated ordered collagen deposition and mature microvessel formation, achieving a 73.10% wound closure rate at day 7 and 58.01% collagen deposition fraction at day 14, thus exhibiting equivalent or superior repair capacity compared with commercial hydrogel dressings. This carrier-free supramolecular system based on natural herbal small molecules provides a safe, convenient, and integrated therapeutic strategy for diabetic infected chronic wounds, with promising clinical translation potential. Full article

Type 2 diabetes mellitus (T2DM) remains a global health crisis, with nearly 589 million adults currently affected and projections pointing toward 853 million by 2050. Despite an expanding pharmacological armamentarium, a significant proportion of patients fail to achieve adequate glycaemic control, and the limitations of existing therapies, including adverse effects, cost, and limited accessibility, underscore the compelling need for novel therapeutic approaches. Phytochemicals such as curcumin, berberine, quercetin, resveratrol, and epigallocatechin gallate possess well-documented antidiabetic activity, operating through the PI3K/Akt, AMPK (activated protein kinase), NF-κB/JNK (nuclear factor kappa-B), and GLP-1R (glucagon-like peptide-1) signalling axes to improve insulin sensitivity, suppress gluconeogenesis, protect pancreatic beta-cells, and attenuate chronic metabolic inflammation. However, their clinical utility has been fundamentally constrained by poor oral bioavailability arising from low aqueous solubility, gastrointestinal instability, extensive first-pass metabolism, and P-glycoprotein-mediated efflux. Advanced drug delivery systems, including liposomes, solid lipid nanoparticles (SLN), nanostructured lipid carriers, PLGA (Poly (lactic-co-glycolic acid)) and chitosan nanoparticles, nanoemulsions, self-nanoemulsifying drug delivery systems, and phytosomes have demonstrated the capacity to overcome these barriers, achieving five- to ten-fold improvements in systemic bioavailability and substantially enhanced antidiabetic efficacy in preclinical models. Emerging mechanistic evidence further positions gut microbiota modulation and epigenetic reprogramming as additional therapeutic axes through which nano-encapsulated phytochemicals may exert durable metabolic benefits. Nonetheless, critical translational challenges persist, encompassing nanotoxicological risks, herb–drug interactions, the absence of harmonised regulatory frameworks for nano-phytomedicine products, phytochemical raw material variability, and formidable technical and economic barriers to scalable nanoparticle manufacturing. This review synthesises the current mechanistic, formulation, and clinical evidence within a unified analytical framework and identifies the strategic priorities of rigorous clinical development, regulatory clarity, and manufacturing standardisation required to translate nano-phytomedicine science into evidence-based T2DM therapeutics. Full article

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for the management of inflammatory disorders, pain, and fever due to their significant anti-inflammatory and antipyretic properties. However, their long-term use is often associated with multiple adverse effects, including gastric erosion, hemorrhage, and perforation, as well as cardiovascular, hepatic, and renal complications. Indomethacin is a potent NSAID commonly used in the treatment of pain and rheumatoid arthritis. Its poor water solubility, Biopharmaceutics Classification System (BCS) Class II, results in low aqueous solubility and high membrane permeability, and conventional dosage forms often fail to overcome pharmacokinetic limitations and gastrointestinal irritation. To address these drawbacks, alternative indomethacin-loaded drug delivery systems have been developed, which enable controlled release, enhanced solubility, and targeted delivery for improving therapeutic efficacy and safety profile. Nature provides a diverse reservoir of bioactive compounds with significant anti-inflammatory potential, making them promising alternatives or complementary agents to indomethacin. Representative examples include the alkaloids piperine and berberine; the flavonoids oleocanthal and apigenin; and the terpenoids thymoquinone, kahweol, and cafestol; as well as anthraquinones and iridoids. This review summarizes the current evidence on plant-derived anti-inflammatory compounds that may “replace” or act synergistically with indomethacin. In addition, we discuss the pharmacological properties of indomethacin and recent advances in drug delivery systems designed to improve its topical and systemic therapeutic applications. Full article

Skin pigmentation is regulated by intrinsic and extrinsic factors and is closely associated with melanogenesis and cellular homeostasis. Autophagy is a cellular self-digestion process that contributes to homeostatic regulation, but its role in melanogenesis remains to be further clarified. This study investigated whether berberine chloride (BBC), an isoquinoline alkaloid, modulates melanin production through autophagy-related signaling in B16-F1 melanoma cells. Tyrosinase activity was examined by tyrosinase zymography, extracellular melanin levels in the culture supernatant were measured after BBC treatment, and the expression of melanogenesis-, mitogen-activated protein kinase (MAPK)-, and autophagy-related proteins was analyzed by Western blotting. BBC inhibited tyrosinase activity and reduced extracellular melanin levels in a dose-dependent manner. BBC also increased phosphorylated extracellular signal-regulated kinase (p-ERK) levels while decreasing melanogenesis-related protein expression. In addition, BBC modulated MAPK signaling and the expression of autophagy-associated proteins. Small interfering RNA-mediated knockdown of Atg5, Beclin1, or ERK partially restored extracellular melanin levels in BBC-treated cells. These findings suggest that BBC suppresses melanogenesis in B16-F1 melanoma cells in association with ERK and autophagy-related signaling. Full article

Canine osteosarcoma is an aggressive primary bone malignancy associated with a poor prognosis and a high propensity for lung metastasis. Due to the limitations and side effects of conventional chemotherapy, there remains a pressing need for alternative therapeutic strategies and adjuvants. In this study, we examined the effects of berberine chloride (BBRC), a bioactive isoquinoline alkaloid derived from the dried roots of Coptidis Rhizoma, on canine osteosarcoma D-17 and DSN cell lines. BBRC reduced the viability and migratory capacity of D-17 and DSN cell lines in three-dimensional (3D) spheroid cultures. Additionally, BBRC induced calcium ion overload in the mitochondrial matrix but not in the cytoplasm, in both osteosarcoma cell lines. BBRC also triggered excessive generation of reactive oxygen species (ROS) in both cell lines. Furthermore, Western Blot analysis revealed that BBRC downregulated the MMP2/AKT/β-catenin signaling pathways in both BBRC in D-17 and DSN cells. In addition, BBRC downregulated Cyclin D1 and Survivin, known downstream targets of the β-catenin pathway. We also confirmed that BBRC suppressed the transcription of genes involved in cell cycle regulation. Overall, our findings indicate that BBRC inhibits osteosarcoma cell growth by modulating calcium-redox homeostasis and the MMP2/AKT/β-catenin pathway. Full article

Programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) blockade can produce durable responses, but primary and acquired resistance are common. Treatment outcome is influenced by antigen presentation, T-cell localization, suppressive myeloid populations, metabolic stress, and the gut microbiome, all of which shape the tumor immune microenvironment (TIME). This review examines natural bioactive molecules in relation to these resistance features rather than grouping them by chemical class. Castalagin/camu-camu, ginseng polysaccharides, and ginsenoside Rh2 have the clearest preclinical evidence from direct PD-1/PD-L1-combination studies; evidence for the curcumin-gasdermin E (GSDME) axis comes from one recent study. Demethylzeylasteral has a well-supported ubiquitin-specific peptidase 22 (USP22)-PD-L1 degradation mechanism, but the reported antibody combination used cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) rather than PD-1/PD-L1. ACT001, berberine, baicalein, and several other candidates are supported mainly by indirect evidence of PD-L1 regulation or TIME remodeling. The translational value of these findings depends on exposure, target engagement, model selection, biomarker design, and material quality. Relating each candidate to a defined resistance setting helps distinguish promising combinations from mechanistic leads that still require direct testing. Full article